– Announcement follows recent U.S. government award from the Biomedical Advanced Research and Development Authority supporting development of VIR-2482 – SAN FRANCISCO, Oct. 18, 2022 (GLOBE NEWSWIRE) - ...

Cidara Therapeutics is leveraging its Cloudbreak platform to develop CD388 for universal influenza prophylaxis. Fortunately, they recently enrolled 5,000 subjects in its Phase 2b trial to assess CD388 ...

LEIDEN, the Netherlands--(BUSINESS WIRE)--Leyden Laboratories B.V. (the “Company” or “Leyden Labs”) today announced it has raised $70M in funding to advance its Mucosal Protection Platform. This ...

Please provide your email address to receive an email when new articles are posted on . A single oral dose of baloxavir reduced household transmission of influenza in a phase 3b trial. The drug may be ...

Merck, the New Jersey-based pharmaceutical giant, will pay Cidara stockholders $221.50 a share in the all-cash deal. Cidara is currently developing a drug designed to prevent the flu and has at least ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results of the Phase III CENTERSTONE study of ...

Office-based tests can detect influenza viruses within 15 minutes. No rapid influenza diagnostic test identifies any A subtypes. Nasopharyngeal and nasal specimens have higher yields than throat-swab ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Although ...

Influenza, and not the antiviral treatment for it, is responsible for increased neuropsychiatric risks in pediatric patients, new research suggested. The risk for these events was about 50% lower in ...

The most effective defense against an influenza pandemic would be a directed vaccine to elicit a specific immune response toward the strain or strains of influenza virus. However, until there is an ...